The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?

• CooperVision is expected to drive growth through MyDay premium lenses, Biofinity toric/multifocal products, and myopia control offerings like MiSight (which grew 24% in the prior quarter)
• CooperSurgical's fertility business is projected to return to mid-single-digit growth in the second half, supported by improving IVF market conditions and demand for genomics and consumables
• Asia Pacific remains a significant headwind due to consumer weakness in Japan and China, legacy product rationalization, and rising e-commerce activity where the company has lower exposure

Summary: The Cooper Companies Q3 Fiscal 2026 Earnings Preview

The Cooper Companies (COO) is scheduled to report third-quarter fiscal 2026 earnings on September 9 after market close.

Key Financial Expectations

• Revenue estimate: $1.1 billion (3.6% year-over-year growth)
• EPS estimate: $1.11 per share
• Full-year guidance: Adjusted EPS of $4.58-$4.66 (maintained)
• The company has beaten earnings estimates in the last four consecutive quarters with an average surprise of 5.8%

Business Segment Outlook

CooperVision (Primary Growth Driver):

• Expected strong demand for premium daily silicone hydrogel lenses, particularly the MyDay portfolio
• Biofinity toric and multifocal lenses anticipated to contribute meaningfully
• MyDay multifocal and Energys lenses showing sustained adoption
• MiSight myopia control product delivered 24% growth in prior quarter; momentum expected to continue in Japan and Europe

CooperSurgical:

• Fertility business expected to return to mid-single-digit growth in second half
• Improving IVF market conditions driving demand for genomics, consumables, and Witness laboratory tracking systems

Regional Performance

• Americas and EMEA: Healthy growth expected
• Asia Pacific: Significant headwind due to consumer weakness in Japan and China, legacy product rationalization, and e-commerce challenges

Market Implications

Despite positive business trends, Zacks model assigns COO a Rank #4 (Sell) with 0.00% Earnings ESP, suggesting uncertainty around beating estimates. The stock has declined 7.3% year-to-date, underperforming the S&P 500's 12.2% gain. Profitability may face margin pressure from forex headwinds, tariffs, and freight costs, though restructuring benefits should provide partial offsets.